However, although these studies include eIF4E in breast tumors [8, 24, 25] and, more recently the phosphorylation status of this protein [10, 26], very few studies have addressed the nature of MNK1/2 expression, now considered a potential target for anticancer therapy. This evidence concerns the gene MKNK1 and breast neoplasm.